Sign In
Buy CYTK
$80.01
+0.84 (+1.06%)
At Close: Jun 23, 2026
MYQORZO, a Cardiac Myosin Inhibitor, Directly Addresses Underlying Hypercontractility Associated with Obstructive HCM
This Cytokinetics Director Sold 5,000 Shares in November. Is It Time to Dump the Biopharmaceutical Stock?
10:59am, Friday, 19'th Dec 2025
Cytokinetics is a late-stage biopharmaceutical company targeting muscle function. Its stock has gained almost 30% this year, besting the S&P 500.
Cytokinetics Announces NMPA Approval of MYQORZO® (aficamten) in China for Patients with Obstructive Hypertrophic Cardiomyopathy
07:30am, Wednesday, 17'th Dec 2025
Approval Triggers Milestone Payment of $7.5 Million from Sanofi; Cytokinetics Eligible to Receive Additional Milestone Payments and Royalties on Net Sales in Greater China SOUTH SAN FRANCISCO, Calif
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
04:00pm, Tuesday, 16'th Dec 2025
SOUTH SAN FRANCISCO, Calif., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on December 15, 2025 it granted stock options to purchase an aggregate of
Final Decision from European Commission Expected in Q1 2026 SOUTH SAN FRANCISCO, Calif., Dec. 12, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the Committee
Foresite Capital Goes Bullish on Cytokinetics (CYTK), Snapping Up 458K Shares
01:07pm, Monday, 08'th Dec 2025
Added 458,295 shares of Cytokinetics, a $25,187,893 net position change Transaction represents a 13.8% position relative to 13F reportable assets under management Post-trade stake: 458,295 shares valu
Cytokinetics (NASDAQ:CYTK) EVP Sells $3,461,451.70 in Stock
05:03am, Monday, 08'th Dec 2025
Cytokinetics, Incorporated (NASDAQ: CYTK - Get Free Report) EVP Andrew Callos sold 52,486 shares of the stock in a transaction dated Friday, December 5th. The shares were sold at an average price of $
Why Is Cytokinetics (CYTK) Up 10.4% Since Last Earnings Report?
12:36pm, Friday, 05'th Dec 2025
Cytokinetics (CYTK) reported earnings 30 days ago. What's next for the stock?
Cytokinetics, Incorporated $CYTK Shares Acquired by Commonwealth of Pennsylvania Public School Empls Retrmt SYS
04:09am, Monday, 24'th Nov 2025
Commonwealth of Pennsylvania Public School Empls Retrmt SYS raised its holdings in shares of Cytokinetics, Incorporated (NASDAQ: CYTK) by 8.8% in the second quarter, according to its most recent Form
Cytokinetics: A Heavily Mispriced Cardiovascular Platform
07:40am, Wednesday, 19'th Nov 2025
Cytokinetics is positioned as a precision cardiac mechanics platform leader, with aficamten as the first proof-of-concept and multiple pipeline assets. Aficamten's differentiated REMS, rapid titration
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
04:00pm, Tuesday, 18'th Nov 2025
SOUTH SAN FRANCISCO, Calif., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on November 15, 2025 it granted stock options to purchase 87,297 restricte
CYTK Deadline: CYTK Investors Have Opportunity to Lead Cytokinetics, Inc. Securities Fraud Lawsuit
07:39pm, Monday, 17'th Nov 2025
NEW YORK , Nov. 17, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Cytokinetics, Inc. (NASDAQ: CYTK) between December 27, 2023 and
CYTK LAWSUIT ALERT: Levi & Korsinsky Notifies Cytokinetics, Incorporated Investors - Lead Plaintiff Deadline November 17, 2025
03:59pm, Monday, 17'th Nov 2025
New York, New York--(Newsfile Corp. - November 17, 2025) - If you suffered a loss on your Cytokinetics, Incorporated (NASDAQ: CYTK) investment and want to learn about a potential recovery under the fe
Investors in Cytokinetics, Incorporated Should Contact Levi & Korsinsky Before November 17, 2025 to Discuss Your Rights – CYTK
03:48pm, Monday, 17'th Nov 2025
NEW YORK, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Cytokinetics, Incorporated ("Cytokinetics" or the "Company") (NASDAQ: CYTK) of a class action securities lawsui
New York, New York--(Newsfile Corp. - November 17, 2025) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Cytokinetics, Inc. (NASDAQ: CYTK) between Dece
